These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 21981030)

  • 1. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution.
    Picker SM; Tauszig ME; Gathof BS
    Transfusion; 2012 Mar; 52(3):510-6. PubMed ID: 21981030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.
    Picker SM; Steisel A; Gathof BS
    Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.
    Picker SM; Oustianskaia L; Schneider V; Gathof BS
    Vox Sang; 2009 Jul; 97(1):26-33. PubMed ID: 19302416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies.
    Picker SM; Schneider V; Oustianskaia L; Gathof BS
    Transfusion; 2009 Nov; 49(11):2311-8. PubMed ID: 19624608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.
    Picker SM; Steisel A; Gathof BS
    Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology.
    Li J; Lockerbie O; de Korte D; Rice J; McLean R; Goodrich RP
    Transfusion; 2005 Jun; 45(6):920-6. PubMed ID: 15934990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction.
    Tauszig ME; Picker SM; Gathof BS
    Transfus Apher Sci; 2012 Feb; 46(1):33-7. PubMed ID: 22119364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the automated collection and extended storage of apheresis platelets in additive solution.
    Johnson L; Winter KM; Hartkopf-Theis T; Reid S; Kwok M; Marks DC
    Transfusion; 2012 Mar; 52(3):503-9. PubMed ID: 21880041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?
    van der Meer PF; Bontekoe IJ; Daal BB; de Korte D
    Transfusion; 2015 Aug; 55(8):1900-8. PubMed ID: 25752624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover.
    Johnson L; Winter KM; Reid S; Hartkopf-Theis T; Marschner S; Goodrich RP; Marks DC
    Vox Sang; 2011 Oct; 101(3):208-14. PubMed ID: 21492184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
    Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
    Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets method.
    Sandgren P; Tolksdorf F; Struff WG; Gulliksson H
    Vox Sang; 2011 Jul; 101(1):35-43. PubMed ID: 21175668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies.
    Picker SM; Schneider V; Gathof BS
    Transfusion; 2009 Jun; 49(6):1224-32. PubMed ID: 19220821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
    Ambruso DR; Thurman G; Marschner S; Goodrich RP
    Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction.
    AuBuchon JP; Herschel L; Roger J; Taylor H; Whitley P; Li J; Edrich R; Goodrich RP
    Transfusion; 2005 Aug; 45(8):1335-41. PubMed ID: 16078923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
    Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
    Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of different hold time before addition of platelet additive solution on the in vitro quality of apheresis platelets.
    Ringwald J; Haager B; Krex D; Zimmermann R; Strasser E; Antoon M; De Schrijver E; Eckstein R
    Transfusion; 2006 Jun; 46(6):942-8. PubMed ID: 16734810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days.
    Cookson P; Thomas S; Marschner S; Goodrich R; Cardigan R
    Transfusion; 2012 May; 52(5):983-94. PubMed ID: 22014032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.
    Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC
    Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma.
    Tonnetti L; Proctor MC; Reddy HL; Goodrich RP; Leiby DA
    Transfusion; 2010 May; 50(5):1019-27. PubMed ID: 20030791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.